MX2010003630A - Administracion sostenida de analogos de compstatina desde geles. - Google Patents

Administracion sostenida de analogos de compstatina desde geles.

Info

Publication number
MX2010003630A
MX2010003630A MX2010003630A MX2010003630A MX2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A MX 2010003630 A MX2010003630 A MX 2010003630A
Authority
MX
Mexico
Prior art keywords
sustained delivery
gels
compstatin analogs
compstatin analog
compstatin
Prior art date
Application number
MX2010003630A
Other languages
English (en)
Spanish (es)
Inventor
Pascal Deschatelets
Paul Olson
Cedric Francois
Original Assignee
Potentia Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Potentia Pharmaceuticals Inc filed Critical Potentia Pharmaceuticals Inc
Publication of MX2010003630A publication Critical patent/MX2010003630A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Nanotechnology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2010003630A 2007-10-02 2008-10-02 Administracion sostenida de analogos de compstatina desde geles. MX2010003630A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US97691907P 2007-10-02 2007-10-02
US2646008P 2008-02-05 2008-02-05
PCT/US2008/078593 WO2009046198A2 (en) 2007-10-02 2008-10-02 Sustained delivery of compstatin analogs from gels

Publications (1)

Publication Number Publication Date
MX2010003630A true MX2010003630A (es) 2010-04-21

Family

ID=40526950

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010003630A MX2010003630A (es) 2007-10-02 2008-10-02 Administracion sostenida de analogos de compstatina desde geles.

Country Status (12)

Country Link
US (1) US20110182877A1 (https=)
EP (1) EP2207530A4 (https=)
JP (1) JP2010540654A (https=)
KR (2) KR20150080007A (https=)
CN (1) CN101854916A (https=)
AU (1) AU2008308657A1 (https=)
BR (1) BRPI0817524A2 (https=)
CA (1) CA2701470A1 (https=)
MX (1) MX2010003630A (https=)
RU (1) RU2505311C2 (https=)
WO (1) WO2009046198A2 (https=)
ZA (1) ZA201002365B (https=)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
WO2009015087A2 (en) * 2007-07-20 2009-01-29 Potentia Pharmaceuticals, Inc. Compositions and methods for treatment of trauma
EP2278987A4 (en) * 2008-03-28 2012-08-22 Apellis Ag MODULATION AND REPLY / IMPROVEMENT OF THE COMPLEMENTARY SYSTEM IN THE TREATMENT OF TRAUMATISM
TWI492769B (zh) * 2009-09-23 2015-07-21 Alcon Res Ltd 可注射的水性眼用組成物及其使用之方法
US9421240B2 (en) 2010-06-22 2016-08-23 Apellis Pharmaceuticals, Inc. Compstatin analogs for treatment of neuropathic pain
ES2426603T3 (es) 2010-09-03 2013-10-24 Novagali Pharma S.A. Una emulsión de tipo agua en aceite para tratar una enfermedad de los ojos
GEP201706606B (en) 2010-09-03 2017-01-25 Santen Sas Water-in-oil type emulsion for treating a disease of the eye
US9107822B2 (en) 2010-09-03 2015-08-18 Santen Sas Water-in oil type emulsion for treating a disease of the eye
CN103687867B (zh) 2011-05-11 2017-02-08 阿佩利斯制药公司 细胞反应性的、长效的或靶向的坎普他汀类似物及其用途
CN103796667A (zh) * 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
WO2014028861A1 (en) * 2012-08-17 2014-02-20 Apellis Pharmaceuticals, Inc. Detection of high risk drusen
ES2879430T3 (es) 2012-11-15 2021-11-22 Apellis Pharmaceuticals Inc Análogos de compstatina de acción prolongada y composiciones y métodos relacionados
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
US9940683B2 (en) 2013-07-31 2018-04-10 Elwha Llc Managing a risk of a liability that is incurred if a subject treated for a condition is retreated within a specified time period
US20150039337A1 (en) * 2013-07-31 2015-02-05 Elwha Llc Managing a risk of a liability that is incurred if one or more subjects each treated for a respective condition are retreated within a respective specified time period
EP2918262B1 (en) 2014-03-10 2023-08-09 PLS-Design GmbH Induction of antigen-specific tolerance by peripheral phagocytosis
AU2015274482B2 (en) 2014-06-12 2018-11-08 Ucb Holdings, Inc. Modulation of complement activity
CA2970502A1 (en) * 2014-12-12 2016-06-16 The Schepens Eye Research Institute, Inc. Gdnf induction for the treatment of retinal disorders
EP3250230B9 (en) 2015-01-28 2022-02-23 RA Pharmaceuticals, Inc. Modulators of complement activity
EP3095440B1 (en) 2015-05-19 2020-01-15 PLS-Design GmbH Antigen-specific immunotherapy using tolerizing liposomes
EP3359555B1 (en) * 2015-10-07 2023-12-20 Apellis Pharmaceuticals, Inc. Dosing regimens
ES2941640T3 (es) 2015-12-16 2023-05-24 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento
MX2019006527A (es) 2016-12-07 2019-08-01 Ra Pharmaceuticals Inc Moduladores de la actividad del complemento.
RU2661621C2 (ru) * 2016-12-19 2018-07-17 Александр Николаевич Епихин Способ пролонгации и усиления терапевтического эффекта действия ингибиторов ангиогенеза при лечении неоваскулярных форм макулярных дегенераций
JP2020516607A (ja) 2017-04-07 2020-06-11 アペリス・ファーマシューティカルズ・インコーポレイテッドＡｐｅｌｌｉｓ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ，Ｉｎｃ． 投与レジメンならびに関連組成物および方法
AU2018386304B2 (en) 2017-12-15 2023-12-07 Apellis Pharmaceuticals, Inc. Dosing regimens and related compositions and methods
CN113966224A (zh) 2019-06-04 2022-01-21 Ra制药公司 采用补体抑制剂的炎性疾病治疗

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
PT1549333E (pt) * 2002-09-20 2012-01-03 Univ Pennsylvania Análogos de compstatina com actividade melhorada
MX351152B (es) * 2005-10-08 2017-10-04 Potentia Pharmaceuticals Inc Compstatina y analogos de la misma para tratar trastornos oculares.
US8168584B2 (en) * 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ES2390828T3 (es) * 2005-11-28 2012-11-16 The Trustees Of The University Of Pennsylvania Análogos potentes de la compstatina
CN101346473A (zh) * 2005-12-22 2009-01-14 爱尔康研究有限公司 用于在具有补体因子h的风险变体的患者中预防和治疗年龄相关性黄斑变性的c3-转化酶抑制剂
US20070196367A1 (en) * 2006-02-22 2007-08-23 Valentin Dinu Methods of preventing and treating Alzheimer's disease, age related macular degeneration and other diseases involving extra-cellular debris through the inhibition of the complement system
PL2148691T3 (pl) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Analogi kompstatyny do stosowania w leczeniu stanów zapalnych układu oddechowego

Also Published As

Publication number Publication date
JP2010540654A (ja) 2010-12-24
RU2505311C2 (ru) 2014-01-27
KR20150080007A (ko) 2015-07-08
EP2207530A4 (en) 2013-09-11
US20110182877A1 (en) 2011-07-28
ZA201002365B (en) 2010-12-29
BRPI0817524A2 (pt) 2017-05-02
AU2008308657A1 (en) 2009-04-09
CA2701470A1 (en) 2009-04-09
WO2009046198A2 (en) 2009-04-09
WO2009046198A3 (en) 2009-07-16
CN101854916A (zh) 2010-10-06
KR20100094453A (ko) 2010-08-26
EP2207530A2 (en) 2010-07-21
RU2010113513A (ru) 2011-11-10

Similar Documents

Publication Publication Date Title
MX2010003630A (es) Administracion sostenida de analogos de compstatina desde geles.
Zhang et al. Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates
GB2471304B (en) A pre-filled syringe or autoinjector
WO2012054500A3 (en) Compositions for drug administration
PH12013500741A1 (en) Peptide-based in vivo sirna delivery system
MX2012006998A (es) Composicion antitranspirante/desodorante anhidra liquida.
EP4403197A3 (en) Injectable formulations for organ augmentation
MX2014007233A (es) Composiciones de nucleosidos, nucleotidos y acidos nucleicos modificados.
MX2010005272A (es) Dispensador de gel dosificado.
PT2222669E (pt) Derivados de oxadiazole ativos em esfingosina-1-fosfato (s1p)
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
PH12015500850A1 (en) Stable preservative-free mydriatic and anti-inflammatory solutions for injection
EA201171335A1 (ru) Вектор гена
MX2010009222A (es) Soluciones farmaceuticas, proceso de preparacion y usos terapeuticos.
TN2012000261A1 (en) Aerosol formulation for copd
MX2014002062A (es) Nanoparticulas de peptido y usos de las mismas.
AR074046A1 (es) Envase para la administracion iontoforetica de un farmaco
ZA200807027B (en) Peptides and peptide derivatives, the production thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
EA201591188A1 (ru) Доставка глатирамера ацетата через слизистую оболочку
AR081875A1 (es) Utilizacion de la asociacion de un inhibidor de la corriente sinusal iy de un inhibidor de la enzima de conversion de la angiotensina para el tratamiento de la insuficiencia cardiaca
WO2011064316A3 (en) Mucosal delivery compositions comprising a peptide complexed with a crown comppound and/or a counter ion
CO6160332A2 (es) Agente para terapia y/o mejoramiento de coagulacion intravascular diseminada
EP1758923B8 (en) Peptide substance restoring myocardium function
MX2010001429A (es) Mendicamento en polvo para distribucion nasal de ácido ascórbico para reducir la toxicidad inducida por apomorfina hacia rejido ciliaco.
SA112340077B1 (ar) نظام إيصال siRNA داخل الكائن الحي يعتمد على الببتيدات